Clinical trials: Chagas Disease
Chagas Cardiomyopathy, Non-sustained Ventricular Tachycardia
Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death
The primary objective is to compare the efficacy of the treatment using implantable cardioverter defibrillator (ICD) implantation to that of the treatment using amiodarone in the primary prevention of all-cause mortality in…
- Conditions
- Chagas Cardiomyopathy, Non-sustained Ventricular Tachycardia, At Least 10 Points in Rassi Risk Score for Death
- Trial name
- CHAGASICS (NCT01722942)
- Testing
- ICD implantation, amiodarone hydrochloride
- Where
- 20 sites in Brazil
- Volunteers
- 1,100 people
- Sponsor
- InCor Heart Institute
Chagas Disease, Lactation
Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease
The investigators propose to study the transfer of nifurtimox into breastmilk of lactating women who receive the drug for the treatment of Chagas disease.
- Trial name
- LACTNFX (NCT01744405)
- Where
- Argentina
- Volunteers
- 12 people
- Sponsor
- Hospital de Niños R. Gutierrez de Buenos Aires
Cardiopathy, Chagas Disease
Outcomes of an Anticoagulation Clinic in an University Hospital
A clinical trial designed to compare the oral anticoagulation control obtained by an anticoagulation clinic and the usual medical care in Chagas and Non-Chagas disease patients.
- Conditions
- Cardiopathy, Chagas Disease, Hemorrhage, Thrombosis
- Trial name
- NCT01006486
- Testing
- Anticoagulation clinic, Standard anticoagulation care
- Where
- Brazil
- Volunteers
- 280 people
- Sponsor
- Federal University of Minas Gerais
Chagas Disease, Heart Diseases
Genetic Architecture of Heart Disease in Rural Brazil
To examine the genetics of human susceptibility to Chagas' disease, a leading cause of heart disease throughout Latin America.
- Conditions
- Chagas Disease, Heart Diseases, Arrhythmia, Heart Failure, Congestive
- Trial name
- NCT00023556
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Chagas Disease
Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients
Multicentric study on Chagas disease that seeks to evaluate a new treatment regimen using the drug benznidazole. Currently, existing treatment regimens are long and have frequent side effects, which leads to a high dropout rate…
- Trial name
- Benlatino (NCT06339710)
- Testing
- benznidazole 300 mg daily 8 weeks
- Where
- 2 sites in Brazil
- Sponsor
- Evandro Chagas Institute of Clinical Research
Chagas Disease
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
This study evaluate the efficacy and safety of benznidazole in the treatment of chronic indeterminate Chagas disease in children.
- Trial name
- NCT04024163
- Testing
- Benznidazole
- Where
- 9 sites in Argentina, Bolivia and 1 more
- Volunteers
- 178 people
- Sponsor
- Insud Pharma
Chagas Disease
Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease
Chagas disease, a parasitic infection caused by Trypanosoma cruzi, is endemic in much of Latin America and affects people throughout the world.
- Trial name
- NuestroBen (NCT04897516)
- Testing
- Short regimen of benznidazole, Short treatment with benznidazole, Standard treatment with benznidazole
- Where
- 6 sites in Argentina
- Volunteers
- 300 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Chagas Disease
Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment
Chagas disease is caused by parasite Trypanosoma Cruzi. In Argentina, there is an estimated of 1.600.000 infected people. Due to migration phenomenon, most cases live in urban areas without vectorial transmission.
- Trial name
- NCT04274101
- Testing
- Clinical Manifestations, Serologic response, Direct method
- Where
- Argentina
- Volunteers
- 900 people
- Sponsor
- Hospital de Niños R. Gutierrez de Buenos Aires
Chronic Chagasic Myocarditis
Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy
The purpose of this study is to evaluate the effectiveness of treatment with G-CSF in patients with chronic heart failure secondary to Chagas disease.
- Trial name
- NCT02154269
- Testing
- Treatment with G-CSF (Granulocyte colony stimulating factor)
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Hospital Sao Rafael
Chagas Disease
A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
Researchers are looking for a better way to treat children who have an infectious disease caused by the parasite Trypanosoma cruzi (Chagas' disease).
- Trial name
- NCT02625974
- Testing
- Nifurtimox (Lampit, BAYA2502)
- Where
- 25 sites in Argentina, Bolivia and 1 more
- Volunteers
- 330 people
- Sponsor
- Bayer
Chagas Disease
Congenital Transmission of Lineages I and II of Trypanosoma Cruzi
T. cruzi has been divided into two main lineages: T. cruzi I (TcI) and T. cruzi II (TcII, including all non-TcI). TcI is predominant in Mexico and Central America, while TcII (non-TcI) is predominant in most of South America…
- Trial name
- NCT01787968
- Where
- 5 sites in United States, Argentina and 3 more
- Volunteers
- 28,348 people
- Sponsor
- Tulane University School of Public Health and Tropical Medicine
Chagas Cardiomyopathy
Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
Chagas disease is considered by the World Health Organization (WHO) as one of the most neglected tropical diseases in the world, having relevance in many Latin America countries.
- Trial name
- ANSWER-HF (NCT04853758)
- Testing
- Sacubitril / Valsartan Oral Tablet [Entresto], Enalapril
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- University of Sao Paulo General Hospital
Chagas Disease, Colchicine Resistance
Colchicine for Patients With Chagas´ Disease( B1 Stage)
This study evaluate the addition of colchicine in the treatment of patients with Chagas´disease. Forty patients will receive colchicine while twenty patients will receive placebo
- Trial name
- COACH (NCT03704181)
- Testing
- Colchicine 0.5 MG twice day for one year
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo General Hospital
Chagas Disease, Cardiomyopathy
Exercise Training in Chagas Cardiomyopathy
The benefits of exercise training in heart failure are well established. Its effects, however, have not been evaluated in Chagas cardiomyopathy (ChC).
- Conditions
- Chagas Disease, Cardiomyopathy, Exercise Training
- Trial name
- NCT01006473
- Testing
- Exercise training
- Where
- Brazil
- Volunteers
- 37 people
- Sponsor
- Federal University of Minas Gerais
Visceral Leishmaniasis, Chagas Disease
A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects
The purpose of this first-in-human study is to generate the necessary safety, tolerability, and pharmacokinetics (PK) information that will support further clinical development of LXE408 for the treatment of patients with…
- Trial name
- NCT07809919
- Testing
- LXE408, Iohexol
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chagas Disease
Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients
This study will evaluate the bioequivalence as well as safety and tolerability of a novel 30 mg tablet of nifurtimox compared to the corresponding marketed 120 mg tablet in adult subjects suffering from chronic Chagas' disease…
- Trial name
- NCT01927224
- Testing
- Nifurtimox (BAYa2502) (4 x 30 mg tablet), Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water), Nifurtimox (BAYa2502) (120 mg tablet)
- Where
- Argentina
- Volunteers
- 37 people
- Sponsor
- Bayer
Chagas Disease With Heart Failure
Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS)
The main purpose of the study is to determine noninvasive markers of brain involvement in Chagas disease. In a subgroup of patients with high intensity transient signals (HITS) on transcranial Doppler monitorization, the…
- Trial name
- CLINICS (NCT01650792)
- Testing
- Aspirin
- Where
- Brazil
- Volunteers
- 500 people
- Sponsor
- Federal University of Bahia
Parasitemia, Protozoan Infections
Chagas Disease Diagnostic - Inconclusive Serology
T. cruzi infection affects approximately five million people in Brazil. The diagnosis of the chronic phase of infection is performed by indirect serological methods which, nevertheless, leave inconclusive results.
- Trial name
- NCT00511589
- Testing
- chagas disease diagnostic
- Where
- Brazil
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Chagas Cardiomyopathy, Heart Failure
A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
Chronic Chagas cardiomyopathy causes substantial morbidity and mortality in Latin America. Whether RAS inhibitors and beta-blockers are safe and beneficial has been challenged because of the lack of formal trials.
- Conditions
- Chagas Cardiomyopathy, Heart Failure, Dilated Cardiomyopathy
- Trial name
- NCT01557140
- Testing
- RASi plus carvedilol
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Federal University of Minas Gerais
Chagas Disease
Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age
The investigators are proposing to perform a double-blinded, non-inferiority randomized controlled trial comparing a short 30-day treatment with BZN 150mg/day (30d/150mg) vs. a 60-day treatment with BZN 300 mg/day (60d/300mg).
- Trial name
- BETTY (NCT03672487)
- Testing
- Benznidazole
- Where
- 3 sites in United States, Argentina
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Tulane University School of Public Health and Tropical Medicine